FrançaisAre analysts right about Healthpeak Properties (DOC)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Healthpeak Properties, we replayed every analyst price target of the past 12 months and measured the real outcome: 16% were profitable, average return -8% (45 calls). At 3 months: -0% average return (26% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| RBC Capital | 6 | 0% | -20% |
| Mizuho | 5 | 20% | -2% |
| Scotiabank | 5 | 20% | +1% |
| Wedbush | 5 | 0% | -12% |
Valuation
Is Healthpeak Properties overvalued, and is it a good time to buy Healthpeak Properties right now? If you're wondering, here's a recap to make up your own mind: Healthpeak Properties's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Healthpeak Properties | Sector median (Real Estate) |
|---|---|---|
| P/E | 62.4 | 29.5 |
| Forward P/E | -141.5 | 34.2 |
| Net margin | 8% | 25% |
👉 Healthpeak Properties trades above its sector median (62.4 vs 29.5) — the market expects higher growth; watch out for disappointment.
📖 P/E, PEG, margin…: see the glossary
💵 Dividend : Healthpeak Properties pays about $1.22/share/yr → 5.66% yield. what is this?
Frequently asked questions
Is Healthpeak Properties a buy right now?
The analyst consensus on Healthpeak Properties (DOC) is "Hold" (13 bullish, 0 bearish calls over 12 months). This is not advice: historically, 16% of their targets on this stock turned out profitable over 1 year.
What is Healthpeak Properties's price target?
The median 12-month price target is $22.50 (+6% vs $21.22), ranging from $21.00 to $24.00 (12 analysts).
Are analysts accurate on Healthpeak Properties?
Over 1 year, 16% of analyst targets on Healthpeak Properties were profitable, for an average return of -8% (across 45 timestamped calls). This is JPI Invest's accuracy metric.
What is the Healthpeak Properties stock forecast?
Analysts target a median of $22.50 within 12 months, i.e. +6% vs the current price. The most bullish targets $24.00, the most cautious $21.00.
What is the Healthpeak Properties stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $22.50, +6%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (16%), and the stock's past trajectory.
Is Healthpeak Properties overvalued?
Its P/E is 62.4, forward P/E -141.5. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of Healthpeak Properties →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.